profit from every $100 of sales.
$0$100
Pro-Dex
$65.66-2.61% today
+106.2% in 1 year
1-year low $28.911-year high $73.41
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $23.40 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Pro-Dex sold, what it kept, and what it did with the cash.
Sales went from $42.0 million in 2022 to $66.6 million in 2025, with $8.98 million of profit last year.
SalesProfit
Pro-Dex vs. similar companies
Pro-Dex grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pro-Dex | 23.4× · Fair price | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Pro-Dex's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 42 | 46 | 54 | 67 | |
| 13 | 13 | 15 | 20 | |
| 5 | 6 | 7 | 11 | |
| 7 | 11 | 4 | 14 | |
| 5 | 7 | 2 | 9 | |
| 1.02 | 1.98 | 0.60 | 2.67 | |
| 31.2% | 27.7% | 27.0% | 29.3% | |
| 12.3% | 12.5% | 13.3% | 16.1% | |
| 10.9% | 15.3% | 4.0% | 13.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 49 | 52 | 52 | 61 |
| Cash | 1 | 3 | 3 | 0 |
| Total debt | 16 | 15 | 14 | 17 |
| Total liabilities | 24 | 20 | 22 | 25 |
| 25 | 32 | 31 | 37 | |
| 4 | 4 | 4 | 3 | |
| 11.8% | 17.0% | 5.7% | 19.1% | |
| 18.0% | 22.4% | 6.9% | 24.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | 5 | 6 | -2 | |
| 2 | 1 | 1 | 1 | |
| -3 | 4 | 5 | -3 | |
| Dividends paid | – | – | – | – |
| 2 | 2 | 4 | 4 | |
| 1 | 1 | 1 | 1 |
Valuation
- 23.4×
- 27.6×
- 0.62
- 4.0×
- 3.2×
- –
- 16.0×
- -1.4%
- 4.3%
- 0.0%
Profitability
- 29.3%
- 16.1%
- 13.5%
- 26.3%
- 12.3%
- 11.8%
- 29.1%
- 16.0%
- 17.9%
- 4.3%
Growth
- +16.6%
- +37.8%
- −156.1%
- –
- −3.5%
Financial health
- 0.5×
- 0.45
- 26.9%
- 14.1×
- 3.67
- 2.14
- 1.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 20%of 952
Top 31%of 884
Top 45%of 601
Top 33%of 886
Bottom 31%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 1.20 | 0.62 | +93.5% |
| Jan 29, 2026 | 0.66 | 0.59 | +11.9% |
| Oct 30, 2025 | 0.62 | 0.50 | +24.0% |
| Sep 4, 2025 | 0.36 | 0.47 | −23.4% |
| May 1, 2025 | 0.98 | 0.47 | +108.5% |
| Jan 30, 2025 | 0.61 | 0.38 | +60.5% |
| Oct 31, 2024 | 0.75 | 0.29 | +158.6% |
| Sep 5, 2024 | 0.46 | 0.35 | +31.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
58No pass
Philip Fisher
66Pass
Peter Lynch
89Pass
Joel Greenblatt
32No pass
Charlie Munger
51No pass
Terry Smith
38No pass
Questions about Pro-Dex
Is Pro-Dex a good stock to buy?
A solid business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pro-Dex AI analysis
What does Pro-Dex do?
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. It is in Medical - Instruments & Supplies.
Does Pro-Dex pay a dividend?
No. Pro-Dex does not pay a dividend at the moment; in 2025 it returned $3.50 million to shareholders by buying back its own shares.
Is Pro-Dex stock halal?
Yes. Pro-Dex passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has Pro-Dex stock done over the past year?
Up 106.2% over the past twelve months, to $65.66. It traded between $28.91 and $73.41 and is 10.6% below its high.
Who are Pro-Dex's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Pro-Dex's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.